Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06563323 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)

Study acronym: GEORGE
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing Show 5 more changesShow less
    • Study completion pushed from Aug 13, 2027 to Oct 5, 2027
    • Eligibility criteria expanded, about 23 words
    • Secondary endpoints: details revised at 6 of 13 entries
    • Site details revised at 2 of 2 sites
    • Publications: details revised at 10 of 10 entries
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 2
    • Start date changed from estimate of Jan 1, 2025 to Feb 1, 2025
    v3
  3. Secondary endpoints: 15 to 13
    • Eligibility criteria expanded, about 5 words
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A single-arm open-label study assessing short-term (week 6, 16) and long-term (week 32) efficacy of guselkumab in adult participants with pyoderma gangrenosum (PG)
Trial Details
NCT Number NCT06563323
Lead Sponsor Oregon Health and Science University
Collaborators: Janssen Scientific Affairs, LLC, Ohio State University
Conditions
(from sponsor)		 Pyoderma Gangrenosum, Skin Diseases, Wound Heal, Pyoderma, Skin Ulcer
Related terms Pyoderma, Pyoderma Gangrenosum, Skin Diseases, Skin Ulcer
Enrollment 17 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov